A study investigating the use of Prevo-Check® for the early detection of HPV16-induced anal cancer has been shortlisted for a UK Diagnostics Award in the category “Pilot of the Year”. Conducted by the German Competence Network for HIV/AIDS, the retrospective study showed that Prevo-Check® would have helped achieving an anal cancer diagnosis up to 9.5 months earlier than current standard of care.
The results will shortly be presented in more detail at EUROGIN, an international conference on HPV-induced disease . The award entry also discussed the implications of these results and how screening with Prevo-Check® could improve decision-making by health care professionals both at community and at secondary level.
Shortlisted candidates were selected by a panel of high-ranking professionals from the National Health Services (NHS) and industry, including the Chief Executive of the British IVD Association (BIVDA). The winners of the awards will be announced during the UK Diagnostic Summit taking place in Manchester on November 28th.
The 2019 Diagnostic Summit will bring together diagnostic developers in academia and industry as well as end-users in the pharmaceutical and healthcare sector to gain a comprehensive picture of diagnostics in a variety of fields ranging from oncology to infectious diseases.